FOGHORN THERAPEUTICS INC.

FHTX

CIK 0001822462 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$9M
↑+223.8% +$6Mvs FY2024 (Q4)
Gross Profit
$9M
↑+223.8% +$6Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Excellent
83/100
  • Profitability
    100ROIC 88.6% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 2.73 (above 1.5 = solid)
  • Leverage
    100D/E 0.00 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.13x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +223.8% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -226.9% · trend +119.8pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$50K
investment in PP&E
Stock-based comp (TTM)
$10M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$198M
everything owned
Total liabilities
$307M
everything owed
Stockholders' equity
$-109M
shareholder claim
Net debt
$-81M
Net cash position ($81M)

Recent performance · 26 quarters

Revenue↑+223.8% +$6M
$9M
Net Income↑+17.1% +$3M
$-16M
Free Cash Flow↑+100.0% +$479K
$0
Operating Margin↑+78.6pts
-226.9%

Drill down